Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Sirus Khodadadi"'
Site-Specific PEGylation of Recombinant Immunotoxin DAB389IL-2: Structural and Functional Assessment
Autor:
Nasrin Zarkar, Mohammad Ali Nasiri Khalili, Sirus Khodadadi, Mehdi Zeinoddini, Maryam Ghodrati Siahmazgi, Nasrin Faramarzi
Publikováno v:
Research in Molecular Medicine, Vol 7, Iss 4, Pp 7-16 (2019)
Background: DAB389IL-2 is considered a fusion immunotoxin and it is used for the CTCL therapy. DAB389IL-2 includes of two distinct portions; the catalytic domain of diphtheria toxin and IL-2. DAB389IL-2 duo to the presence of a free cysteine residue
Externí odkaz:
https://doaj.org/article/1f9e09435f8d4fad9bf975ab509ce282
Publikováno v:
Protein & Peptide Letters. 29:293-305
Background and objective: Recombinant human granulocyte-colony stimulating factor (rhG-CSF) and its PEGylated form (PEG-GCSF) are used in the cancer therapy. Thus the development of a more cost-effectively method for expressing rhG-CSF and the PEGyla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a27001bbd59e0738e881fb8912c13b6a
https://doi.org/10.2174/0929866529666220126100559
https://doi.org/10.2174/0929866529666220126100559
Autor:
Mohammad Ali Khalili, Sirus Khodadadi, Maryam Ghodrati Siahmazgi, Mehdi Zeinoddini, Fathollah Ahmadpour
Publikováno v:
Current Computer-Aided Drug Design. 16:238-244
Background:Chemotherapy and radiotherapy have negative effects on normal tissues and they are very expensive and lengthy treatments. These disadvantages have recently attracted researchers to the new methods that specifically affect cancerous tissues
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b18ceeabe8b1e2fb7e4f1f7e8c7e8985
https://doi.org/10.2174/1573409914666181012151242
https://doi.org/10.2174/1573409914666181012151242
Publikováno v:
Biotechnology and Applied Biochemistry. 67:206-212
DAB389 IL-2 (Denileukin diftitox) is considered an immunotoxin, and it is the first immunotoxin approved by Food and Drug Administration. It is used for the treatment of a cutaneous form of T-cell lymphoma. This fusion protein has two disulfide bonds
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2712a7a02b247d98e755965bb3bf9b5
https://doi.org/10.1002/bab.1833
https://doi.org/10.1002/bab.1833
Autor:
Sirus Khodadadi, Fathollah Ahmadpour, Mehdi Zeinoddini, Mohammad Ali Khalili, Maryam Ghodrati Siahmazgi
Publikováno v:
International Journal of Peptide Research and Therapeutics. 26:767-774
Immunotoxin is a recombinant fusion toxin which has been developed to kill cancer cells selectively. DT389GCSF as a new immunotoxin consists of a truncated diphtheria toxin linked to granulocyte colony stimulating factor (GCSF) via the SerGly4SerMet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e37342d3697da52eba2bfc45a665cb
https://doi.org/10.1007/s10989-019-09884-6
https://doi.org/10.1007/s10989-019-09884-6
Publikováno v:
Current Proteomics. 16:307-313
Background:DAB389IL-2 (Denileukin diftitox) as an immunotoxin is a targeted pharmaceutical protein and is the first immunotoxin approved by FDA. It is used for the treatment of various kinds of cancer such as CTCL lymphoma, melanoma, and Leukemia but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0dd69eb12807075955b271d69f798c0
https://doi.org/10.2174/1570164616666190131150033
https://doi.org/10.2174/1570164616666190131150033
Publikováno v:
Journal of Biomolecular Structure and Dynamics. 35:3176-3181
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8238879326a92816c4e6a8286d70f043
https://doi.org/10.1080/07391102.2016.1248489
https://doi.org/10.1080/07391102.2016.1248489
Autor:
Maryam G, Siahmazgi, Mohammad A N, Khalili, Fathollah, Ahmadpour, Sirus, Khodadadi, Mehdi, Zeinoddini
Publikováno v:
Current computer-aided drug design. 16(3)
Chemotherapy and radiotherapy have negative effects on normal tissues and they are very expensive and lengthy treatments. These disadvantages have recently attracted researchers to the new methods that specifically affect cancerous tissues and have l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f58fef4f8695476b70a0de2252cc1c9
https://pubmed.ncbi.nlm.nih.gov/30318000
https://pubmed.ncbi.nlm.nih.gov/30318000
The rat pheochromocytoma cell line, PC12 that in in-vitro condition under inductive factors differentiate and convert into neuron-like cells. Researches have shown that different factors, for example, NGF and bee venom or its components have differen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7970970501b5ff29b92dd9a42c3f6bd9
Publikováno v:
Applied Biochemistry and Biotechnology. 173:1727-1736
Human induced pluripotent stem cells (hiPSCs) are attractive sources of cells for disease modeling in vitro, and they may eventually provide access to cells/tissues for the treatment of many degenerative diseases. Stepwise differentiation from hiPSCs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6bc58ee063d9522a1a80c4527c30b93
https://doi.org/10.1007/s12010-014-0960-9
https://doi.org/10.1007/s12010-014-0960-9